186 212

Cited 1 times in

Anti-HER2/neu Peptide Producing Vector System for Biologic Therapy - Is It Possible to Mass-produce the Peptide?

 Byeong Woo Park  ;  Ki Suk Kim  ;  Kyung Sup Kim  ;  Eun Kyung Kim  ;  Kyong Sik Lee  ;  Min Kyu Heo 
 YONSEI MEDICAL JOURNAL, Vol.44(1) : 58-64, 2003 
Journal Title
Issue Date
Amino Acid Sequence ; Animals ; Cell Division/drug effects ; Cell Line ; Mice ; Oligopeptides/chemical synthesis ; Oligopeptides/pharmacology ; Peptide Fragments/chemical synthesis* ; Peptide Fragments/pharmacology* ; Receptor, ErbB-2/chemistry* ; Recombinant Proteins/chemical synthesis ; Recombinant Proteins/pharmacology ; Technology, Pharmaceutical* ; Transfection
HER2/neu ; mimetic peptide ; biologic therapy
A humanized monoclonal antibody against HER2 has been using in a clinical setting and has been shown to possess therapeutic properties. A mimetic peptide against HER2 was also reported to bind to the HER2 receptor with some therapeutic potential. Based on a previous report and the sequence of Herceptin, we designed oligonucleotides of anti-HER2 mimetic peptides, named V2 and V3 peptides, in order to develop a peptide-producing vector system for biologic therapy against HER2-overexpressing cancers. We also adopted the sequence of a previously reported mimetic peptide, V1 (Park BW et al. Nat. Biotechnol, 2000, 18: 194-198), as a reference peptide. We examined the effects of the V2 and V3 peptides against the HER2-overexpressing cell lines, SK-BR-3 and T6-17. Transient transfection of the construct expressing V1 and V2 inhibited cell proliferation in HER2-overexpressing cell lines by 20 - 30%, but had no effect on the HER2-negative NIH3T3 cells. The proliferation inhibition shown by V2 was slightly better than that shown by V1. Recombinant peptides V2 and V3 were produced on a large scale in an E. coli system, and the V2 peptide showed anti-HER2-specific tumor cell proliferation inhibition of 10% to 30%. Current results suggest that anti-HER2 mimetic peptides, overexpressed by a constitutive promoter or produced in an E. coli system, could specifically inhibit the proliferation of HER2-expressing cancer cells. Further efforts to augment the biologic specificity and efficacy and to develop new technologies for the purification of the peptide from the E coli system are needed.
Files in This Item:
T200303043.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Eun-Kyung(김은경) ORCID logo https://orcid.org/0000-0002-3368-5013
Park, Byeong Woo(박병우) ORCID logo https://orcid.org/0000-0003-1353-2607
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.